COVID-19 vaccine induced interstitial lung disease

Ayumi Yoshifuji; Kota Ishioka; Yuya Masuzawa; Shuntaro Suda; Saori Murata; Yoshifumi Uwamino; Motoko Fujino; Hiromi Miyahara; Naoki Hasegawa; Munekazu Ryuzaki; Haruhiko Hoshino; Kazuhiko Sekine

doi:10.1016/j.jiac.2021.09.010

COVID-19 vaccine induced interstitial lung disease

Ayumi Yoshifuji, Kota Ishioka, Yuya Masuzawa, Shuntaro Suda, Saori Murata, Yoshifumi Uwamino, Motoko Fujino, Hiromi Miyahara, Naoki Hasegawa, Munekazu Ryuzaki, Haruhiko Hoshino, Kazuhiko Sekine

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.

Original language	English
Pages (from-to)	95-98
Number of pages	4
Journal	Journal of Infection and Chemotherapy
Volume	28
Issue number	1
DOIs	https://doi.org/10.1016/j.jiac.2021.09.010
Publication status	Published - 2022 Jan
Externally published	Yes

Keywords

Adverse events
COVID-19 vaccine
Drug-induced interstitial lung disease

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jiac.2021.09.010

Cite this

@article{6563f551ea5a427ebfd314c5a8f5cd99,

title = "COVID-19 vaccine induced interstitial lung disease",

abstract = "A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.",

keywords = "Adverse events, COVID-19 vaccine, Drug-induced interstitial lung disease",

author = "Ayumi Yoshifuji and Kota Ishioka and Yuya Masuzawa and Shuntaro Suda and Saori Murata and Yoshifumi Uwamino and Motoko Fujino and Hiromi Miyahara and Naoki Hasegawa and Munekazu Ryuzaki and Haruhiko Hoshino and Kazuhiko Sekine",

note = "Funding Information: No funding is supported for this report. Publisher Copyright: {\textcopyright} 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases",

year = "2022",

month = jan,

doi = "10.1016/j.jiac.2021.09.010",

language = "English",

volume = "28",

pages = "95--98",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - COVID-19 vaccine induced interstitial lung disease

AU - Yoshifuji, Ayumi

AU - Ishioka, Kota

AU - Masuzawa, Yuya

AU - Suda, Shuntaro

AU - Murata, Saori

AU - Uwamino, Yoshifumi

AU - Fujino, Motoko

AU - Miyahara, Hiromi

AU - Hasegawa, Naoki

AU - Ryuzaki, Munekazu

AU - Hoshino, Haruhiko

AU - Sekine, Kazuhiko

PY - 2022/1

Y1 - 2022/1

N2 - A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.

AB - A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.

KW - Adverse events

KW - COVID-19 vaccine

KW - Drug-induced interstitial lung disease

UR - http://www.scopus.com/inward/record.url?scp=85115965498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115965498&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2021.09.010

DO - 10.1016/j.jiac.2021.09.010

M3 - Article

C2 - 34580010

AN - SCOPUS:85115965498

SN - 1341-321X

VL - 28

SP - 95

EP - 98

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

IS - 1

ER -

COVID-19 vaccine induced interstitial lung disease

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this